Unlock instant, AI-driven research and patent intelligence for your innovation.
A kind of antitumor pharmaceutical composition and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A composition and anti-tumor technology, applied in the direction of anti-tumor drugs, drug combinations, medical preparations containing active ingredients, etc., can solve the problems that have not yet been reported on harpagoside anti-tumor drug combinations, and achieve cardiotoxicity relief Effect
Active Publication Date: 2022-04-15
BEIJING UNIV OF CHINESE MEDICINE
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0012] At present, there is no report on the combination of harpagoside and other antineoplastic drugs
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
experiment example 1
[0052] Experimental Example 1: Detection of resistance to doxorubicin-induced cardiotoxicity
[0053] 1. Animals and groups
[0054] Mice were purchased from SPEF (Beijing) Biotechnology Co., Ltd.
[0055] After 3 days of adaptive feeding, the mice were randomly divided into normal saline group (Control), doxorubicin group (DOX), doxorubicin+harpagoside group (DOX+HAR), doxorubicin+enalapril group Positive drug group (DOX+ENA) and other 4 groups.
[0056]Both basic and clinical studies have shown that enalapril can reduce doxorubicin-induced cardiotoxicity and improve cardiac function, so it is used as a positive control drug in mouse experiments.
[0057] 2. Preparation of doxorubicin-induced cardiotoxicity model
[0058] After the mice (18-20g) were fixed, they were injected with doxorubicin into the tail vein, the injection concentration was 10 mg / mL, and the injection dose was 5 mg / kg, once every 7 days for 4 consecutive weeks. The normal saline group was injected with...
experiment example 2
[0111] Experimental example 2: Detection of anti-tumor activity
[0112] 1. Test method: Different tumor cells, including liver cancer cells (HepG2 cells) and breast cancer cells (MCF-7 cells), were tested with 8*10 4 The cells were inoculated into 96-well plates (100 μl / well) at a density of / mL, cultured for 24 hours, and then stimulated according to the following groupings. After 24 hours, the cell viability was detected by a microplate reader using the CCK8 method.
[0113] 2. Test groups:
[0114] Group 1: normal group (Control), HAR 50μmol / L, HAR 80μmol / L, HAR 100μmol / L, HAR150μmol / L, HAR 200μmol / L;
[0116] 3. Detection index: The OD value detected by the microplate reader represents the cell viability.
[0117] 4. Statistical method: Graphpad Prism 6.0 was used for data proc...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The present invention relates to the field of pharmaceutical compositions, in particular to an anti-tumor pharmaceutical composition and its application. The pharmaceutical composition comprises the following ingredients in parts by weight: 1-10 parts of doxorubicin and 10-200 parts of harpagoside. The invention also provides the application of the pharmaceutical composition in the preparation of anti-tumor drugs. The applicant unexpectedly found that harpagoside itself has no anti-tumor effect, but when harpagoside is combined with doxorubicin, it can be used to treat breast cancer and liver cancer, and the combined effect of the two is better than that of doxorubicin alone. It is confirmed that the two have a synergistic anticancer effect, and at the same time, harpagoside can also alleviate the cardiotoxicity caused by the anticancer drug doxorubicin.
Description
technical field [0001] The invention relates to the field of pharmaceutical compositions, in particular to an anti-tumor pharmaceutical composition and its application. Background technique [0002] The anthracycline antibiotic doxorubicin (doxorubicin, DOX, molecular weight: 543.519) is widely used as an effective chemotherapy drug in various cancers, such as leukemia, solid tumors, soft tissue sarcoma and breast cancer. However, the dose-dependent cardiotoxicity of DOX severely limits its clinical application. Doxorubicin-induced cardiotoxicity ranges from asymptomatic decreased left ventricular ejection fraction (LVEF), tachycardia and arrhythmias, and cardiomyopathy to myocardial infarction and severe congestive heart failure (grades III to IV). [0003] Dexrazoxane (DRX) is currently the only cardioprotective agent approved by the US Food and Drug Administration (FDA) in combination with DOX for the treatment of cancer. However, it was reported that dexrazoxane could ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More